I-MAB Biopharma Co., Ltd.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
I-Mab to Participate at the Piper Sandler Healthcare Conference 2024-11-21 20:00
I-Mab Reports Third Quarter 2024 Results 2024-11-14 20:00
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer 2024-11-06 20:00
I-Mab to Release Q3 2024 Financial Results on November 14, 2024 2024-10-31 19:00
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024 2024-10-30 19:00
I-Mab to Participate at the Truist Securities BioPharma Symposium 2024-10-28 19:00
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer 2024-09-10 19:00
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference 2024-08-26 19:00
I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC) 2024-08-07 19:00
I-Mab Announces Leadership Transitions 2024-07-15 19:30
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer 2024-06-06 19:00
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers 2024-06-05 19:00
I-Mab to Participate at the Jefferies Global Healthcare Conference 2024-05-22 19:00
I-MAB Filed 2023 Annual Report on Form 20-F 2024-04-30 19:00
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference 2024-04-05 19:00
I-Mab Announces Closing of the Divestiture of Business Operations in China 2024-04-03 04:01
I-Mab Reports Full Year 2023 Financial Results and Business Update 2024-03-15 05:00
I-Mab Signs Agreement to Divest its Assets and Business Operations in China 2024-02-07 19:00
I-Mab Announces Participation at Jefferies and Piper Conferences in November 2023-11-06 21:00
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) 2023-11-02 20:00
1 2 3 4 5 9